Table I.
Expression of MUC1 in different tumours.
| Cancer type | Positive expression rate of MUC1, % (n/total n) (Ref.) | Positive expression rate of MUC1 in patients with different stages, (%) (Ref.) | Overall survival time, months |
|---|---|---|---|
| Lung adenocarcinoma | 86.3 (44/51) (20) | T1a-c, 16.2; T2a-b+T3+T4, 40.6(22) | |
| Breast cancer | 94.2 (49/52) (29) | ||
| Ovarian cancer | 100.0 (19/19) (38); 95.0 (57/60) (39) | ||
| Cholangiocarcinoma | 65.9 (56/85) (43) | Poorly differentiated, 91; moderately differentiated, 84; highly differentiated, 43; T1, 50; ≥T2, 80(43) | MUC1 positive, 29.21; MUC1 negative, 56.48(43) |
| Gallbladder carcinoma | 57.4 (62/108) (51) | T1, 28.6; T2, 42.9; T3, 59.5; T4, 77.3(51) | |
| Liver cancer | 77.1 (74/96) (58) | Poorly differentiated, 92; moderately differentiated, 85; highly differentiated, 53(58) | |
| Thyroid carcinoma | 78.3 (47/60) (62) | I+II, 65.6; III+IV, 92.9(62) | |
| Colorectal cancer | 43.6 (88/202) (70) | I, 20; II, 35; III, 54; IV, 60(70) | |
| Cervical carcinoma | 59.6 (31/52) (74) | FIGO 1a, 33; FIGO 1b1, 50; FIGO 1b2, 67; FIGO 2a, 63; FIGO 2b, 100(74) |